You are in: eMedicine Specialties >
Emergency Medicine > PEDIATRIC
Pediatrics, Urinary Tract Infections and Pyelonephritis
Article Last Updated: Feb 27, 2006
AUTHOR AND EDITOR INFORMATION
Section 1 of 10
Author: Ann G Egland, MD, Consulting Staff, Department of Operational and Emergency Medicine, Walter Reed Army Medical Center
Ann G Egland is a member of the following medical societies: American College of Emergency Physicians, American Medical Association, Association of Military Surgeons of the US, Medical Society of Virginia, and Society for Academic Emergency Medicine
Coauthor(s):
Terrance K Egland, MD, Director, Business Planning and Development, Bureau of Medicine and Surgery
Editors: David S Howes, MD, Residency Program Director, Professor of Medicine, Section of Emergency Medicine, University of Chicago/Pritzker School of Medicine; Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine.com, Inc; Grace M Young, MD, Associate Professor, Department of Pediatrics, University of Maryland Medical Center; John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center; Richard G Bachur, MD, Assistant Professor of Pediatrics, Harvard Medical School; Associate Chief and Fellowship Director, Attending Physician, Division of Emergency Medicine, Children's Hospital of Boston
Author and Editor Disclosure
Synonyms and related keywords:
UTI, cystitis, UTI in children, UTI in infants, urinary tract infection in infants, urinary tract infection in children, urosepsis, pyelonephritis, cystitis, vaginitis, bacterial infection
Background
Urinary tract infections (UTIs) are common in the pediatric age group. Early recognition and prompt treatment of UTIs are important to prevent progression of infection to pyelonephritis or urosepsis and to avoid late sequelae such as renal scarring or renal failure.
Infants and young children with UTI may present with few specific symptoms. Older pediatric patients are more likely to have symptoms and findings attributable to an infection of the urinary tract. Differentiating cystitis from pyelonephritis in the pediatric patient is not always possible, although children who appear ill or who present with fever should be presumed to have pyelonephritis if they have evidence of UTI.
Pathophysiology
UTIs generally begin in the bladder due to ascending infection from perineal contaminants, usually bowel flora such as Escherichia coli. In neonates, infection of the urinary tract is assumed to be due to hematogenous rather than ascending infection. This etiology may explain the nonspecific symptoms associated with UTI in these patients.
After the neonatal period, bacteremia generally is not the cause of UTI. The bladder is the initial primary locus of infection with ascending disease of the upper tract (kidneys) and bacteremia as potential sequelae. Bacterial invasion of the bladder with overt UTI is more likely to occur if urinary stasis or low flow conditions exist. Some causes of these conditions are infrequent or incomplete voiding, reflux, or other urinary tract abnormalities.
Even in the absence of urinary tract abnormalities, cystitis causes vesicoureteral reflux, and it may worsen preexisting reflux. Reflux may cause development of pyelonephritis. Chronic or recurrent pyelonephritis results in renal damage and scarring that may progress to chronic renal failure if it continues or is severe.
Frequency
United States
Prevalence varies based on age and sex.
Mortality/Morbidity
- Generalized bacteremia or sepsis may develop from UTI. Approximately 30% of 1- to 3-month-old infants with UTIs are at risk for developing sepsis. The risk drops to approximately 5% in patients older than 3 months.
- If left untreated, simple cystitis may progress to pyelonephritis. More severe cases have the potential for kidney damage, which may lead to hypertension or renal insufficiency.
- Approximately 5-10% of children with symptomatic UTI and fever develop renal scarring.
Sex
- Uncircumcised males have a higher incidence than circumcised males. Uncircumcised male infants have a higher incidence of UTI than female infants.
- UTIs are more frequent in females than males at all ages with the exception of the neonatal period, during which UTI may be the cause of an overwhelming septic syndrome in male infants younger than 2 months.
- Incidence is highest in sexually active adolescent females.
Age
- Excluding neonates, females younger than 11 years have a 3-5% risk; boys of the same age have a 1% risk.
- UTI is the source of infection in up to 6-8% of febrile infants in the first 3 months of life.
History
History will vary with the age of the patient. History is dependent upon the caregiver in younger children.
- Neonates
- Jaundice
- Hypothermia or fever
- Failure to thrive
- Poor feeding
- Vomiting
- Infants
- Poor feeding
- Fever
- Vomiting, diarrhea
- Strong-smelling urine
- Preschoolers
- Vomiting, diarrhea, abdominal pain
- Fever
- Strong-smelling urine, enuresis, dysuria, urgency, frequency
- School-aged children
- Fever
- Vomiting, abdominal pain
- Strong-smelling urine, frequency, urgency, dysuria, flank pain, or new enuresis
- Adolescents are more likely to have some of the classic adult symptoms. Adolescent girls are more likely to have vaginitis (35%) than UTI (17%). Those diagnosed with cystitis frequently have a concurrent vaginitis.
Physical
- Hypertension should raise suspicion of hydronephrosis or renal parenchyma disease.
- Costovertebral angle (CVA) tenderness
- Abdominal tenderness or mass
- Palpable bladder
- Dribbling, poor stream, or straining to void
- Examine external genitalia for signs of irritation, pinworms, vaginitis, trauma, or sexual abuse.
Causes
- Bacterial infections are the most common.
- E coli is the most common by far, causing 75-90% of UTIs.
- Klebsiella species
- Proteus species
- Enterococcus species
- Staphylococcus saprophyticus
- Adenovirus (rare)
Pediatrics, Appendicitis
Pediatrics, Bacteremia and Sepsis
Pediatrics, Gastroenteritis
Pinworms
Renal Calculi
Urethritis, Male
Urinary Obstruction
Vaginitis
Vulvovaginitis
Other Problems to be Considered
Cystitis
Pregnancy
UTIs
Urolithiasis
Lab Studies
- Urinalysis
- A urine specimen that is found to be positive for nitrite, leukocyte esterase, or blood may indicate a UTI.
- Microscopic examination can evaluate for presence of WBCs (>5 per high-power field), RBCs, bacteria, casts, and skin contamination (eg, epithelial cells).
- A midstream clean catch is appropriate if the patient is old enough to cooperate. Clean skin around the urethral meatus and allow first urine to go into the toilet; then, collect the specimen in a sterile collection cup. Collection may be easier if girls sit facing the toilet.
- A bag specimen is adequate for specific gravity. The specimen may be used if the urine bag is removed immediately after urine is deposited. (These specimens are really only useful if results of the urinalysis are negative.)
- Urine culture
- Urine cultures should be sent to the laboratory even if urinalysis results are inconclusive. Approximately 20% of pediatric patients with UTIs have normal urinalyses results.
- Results are best interpreted with knowledge of the collection method and results of the urinalysis.
- A clean-catch urine sample with more than 100,000 colony-forming units (CFU) of a single organism is classic criteria for UTI.
- Judgment must be used in interpreting a clean-catch specimen that reports any growth. If the specific gravity of the urine was low, 60,000-80,000 CFU may be significant.
- Lower colony counts may be significant if present on a repeat culture. Contamination with perineal flora may mask an existing UTI.
- Urinary tract abnormalities may be associated with multiple organisms.
- Cultures with growth of more than 10,000 pure CFU/mL from bladder catheterization or >1000 pure CFU/mL from suprapubic aspiration should be considered significant for UTI.
- Cultures from bagged urine specimens are significant only if there is no growth. Cultures from bag specimens should only be used for relatively well children who will not receive empiric antibiotics for fever. In general, young infants with high fever should never have a bag specimen sent for culture given the consequences of an uninterpretable positive culture.
- Better results may be obtained if the perineum is cleaned and dried before the bag is placed and if the collected urine is removed as soon as the patient voids.
- Electrolyte abnormalities may be present.
- An increased blood urea nitrogen (BUN) finding in a child older than 2 months should raise suspicion of hydronephrosis or renal parenchyma disease.
Imaging Studies
- Imaging typically is delayed 3-6 weeks after the infection as part of outpatient follow-up, except in cases in which urinary tract obstruction is suspected.
- Renal ultrasound
- This study adequately depicts kidney size and shape, but it poorly depicts ureters and provides no information on function.
- A renal ultrasound can diagnose urolithiasis, hydronephrosis, hydroureter, ureteroceles, and bladder distention and has replaced the intravenous pyelogram (IVP) in many cases.
- A voiding cystourethrogram (VCUG) adequately depicts urethral and bladder anatomy and detects vesicoureteral reflux (VUR).
- Nuclear cystography
- This study is good for visualizing the bladder and detecting VUR, but it does not show the urethra.
- It has only a small fraction of radiation dose (~1%) compared to fluoroscopic study.
- It can be used for serial follow-up studies and screening of siblings.
- Nuclear cortical scanning
- This study most frequently uses technetium Tc 99m dimercaptosuccinic acid (DMSA).
- This study detects tubular damage and scarring and shows the kidney outline, but it does not show the collecting system.
- Radiation exposure is low.
Procedures
- Catheterization of the urinary bladder or suprapubic bladder aspiration may be required in patients who cannot provide a midstream clean-catch urine sample.
- A suprapubic tap is the most invasive diagnostic procedure, but many practitioners view it as the criterion standard despite the potential for gross or microscopic hematuria.
Prehospital Care
Patients do not generally present via EMS.
Emergency Department Care
Treatment must be tailored to the presentation of the patient.
- Septic or toxic patients require aggressive management in the ED.
- Intravenous fluid replacement and parenteral antibiotics are indicated.
- Initially, all ill-appearing patients with febrile UTIs should be treated with parenteral antibiotics and monitored as an inpatient.
- Oral fluids and medications may be used for patients with cystitis who are less seriously ill at presentation.
Consultations
Consultation with a urologist typically is not required at presentation unless there is evidence of obstruction of the urinary tract.
Start antibiotics after urinalysis and culture are obtained. A 10-day course of antibiotics is recommended, even for uncomplicated infection. Do not use short-course therapy in children because it is more difficult to differentiate cystitis from pyelonephritis. An exception is the use of short-course therapy in adolescent females with classic cystitis.
Drug Category: Antibiotics
Empiric antibiotics should be chosen for coverage of E coli and for Enterococcus, Proteus, and Klebsiella species. For suspected pyelonephritis, a combination of parenteral antibiotics is recommended. Recent evidence indicates that oral antibiotics are adequate therapy for febrile UTIs in young infants and children; short-term (fever) and long-term (renal scarring) outcomes are comparable to parenteral therapy. For uncomplicated cystitis, oral antibiotic therapy is generally adequate.
| Drug Name | Ampicillin (Omnipen, Principen) |
| Description | Provides bactericidal activity against susceptible organisms. Administered parenterally and used in combination with gentamicin or cefotaxime. |
| Adult Dose | 1-2 g/d IV/IM divided q6h |
| Pediatric Dose | 100-200 mg/kg/d IV/IM divided q6h |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid and disulfiram elevate levels; allopurinol decreases effects and has additive effects on ampicillin rash; may decrease effects of PO contraceptives |
| Pregnancy | B - Usually safe but benefits must outweigh the risks.
|
| Precautions | Adjust dose in renal failure; evaluate rash and differentiate from hypersensitivity reaction; caution in cephalosporin allergy |
| Drug Name | Gentamicin (Garamycin) |
| Description | Aminoglycoside antibiotic for gram-negative coverage. Provides synergistic activity with ampicillin against gram-positive bacteria including enterococcal species. Inhibits protein synthesis by irreversibly binding to bacterial 30S and 50S ribosomes. Dosing regimens are numerous; adjust dose based on CrCl and changes in volume of distribution. May be administered IV/IM. |
| Adult Dose | 3-5 mg/kg IV qd; alternatively, 1 mg/kg IV q8h |
| Pediatric Dose | <5 years: 2.5 mg/kg/dose IV/IM q8h >5 years: 1.5-2.5 mg/kg/dose IV/IM q8h |
| Contraindications | Documented hypersensitivity; non–dialysis-dependent renal insufficiency |
| Interactions | Coadministration with other aminoglycosides, cephalosporins, penicillins, and amphotericin B may increase nephrotoxicity; aminoglycosides enhance effects of neuromuscular blocking agents thus prolonged respiratory depression may occur; coadministration with loop diuretics may increase auditory toxicity of aminoglycosides; possible irreversible hearing loss of varying degrees may occur (monitor regularly) |
| Pregnancy | D - Unsafe in pregnancy
|
| Precautions | Narrow therapeutic index (not intended for long-term therapy); caution in renal failure (not on dialysis), myasthenia gravis, hypocalcemia, and conditions that depress neuromuscular transmission; adjust dose in renal impairment |
| Drug Name | Cefotaxime (Claforan) |
| Description | Third-generation cephalosporin with gram-negative spectrum. Lower efficacy against gram-positive organisms. Used as initial parenteral therapy for pediatric patients with acute complicated pyelonephritis. May be used for neonates or jaundiced patients. Requires dosing at q6-8h intervals. |
| Adult Dose | 1-2 g IV/IM q6-8h |
| Pediatric Dose | 100-200 mg/kg/d IV/IM divided q6-8h |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid may increase levels; coadministration with furosemide and aminoglycosides may increase nephrotoxicity |
| Pregnancy | B - Usually safe but benefits must outweigh the risks.
|
| Precautions | Adjust dose in severe renal impairment; has been associated with severe colitis; caution in penicillin allergy |
| Drug Name | Amoxicillin (Amoxil, Trimox) |
| Description | Interferes with synthesis of cell wall mucopeptides during active multiplication, resulting in bactericidal activity against susceptible bacteria. Activity against gram-positive and some gram-negative bacteria.
|
| Adult Dose | 250-500 mg PO q8h |
| Pediatric Dose | 30-50 mg/kg/d PO divided q8h |
| Contraindications | Documented hypersensitivity |
| Interactions | Reduces the efficacy of PO contraceptives |
| Pregnancy | B - Usually safe but benefits must outweigh the risks.
|
| Precautions | Adjust dose in renal impairment; caution in cephalosporin allergy |
| Drug Name | Trimethoprim and sulfamethoxazole (Bactrim DS, Septra) |
| Description | Inhibits bacterial growth by inhibiting synthesis of dihydrofolic acid. Antibacterial activity of TMP-SMZ includes common urinary tract pathogens, except Pseudomonas aeruginosa. |
| Adult Dose | 160 mg TMP/800 mg SMZ PO bid (ie, 1 double-strength tab bid) |
| Pediatric Dose | <2 months: Not recommended >2 months: 5-10 mg/kg/d PO divided q12h, based on TMP component |
| Contraindications | Documented hypersensitivity; megaloblastic anemia due to folate deficiency; age <2 mo |
| Interactions | May increase PT when used with warfarin (perform coagulation tests and adjust dose accordingly); coadministration with dapsone may increase blood levels of both drugs; coadministration of diuretics increases incidence of thrombocytopenia purpura in elderly persons; phenytoin levels may increase with coadministration; may potentiate effects of methotrexate in bone marrow depression; hypoglycemic response to sulfonylureas may increase with coadministration; may increase levels of zidovudine |
| Pregnancy | C - Safety for use during pregnancy has not been established.
|
| Precautions | Discontinue at first appearance of skin rash or sign of adverse reaction; obtain CBCs frequently; discontinue therapy if significant hematologic changes occur; goiter, diuresis, and hypoglycemia may occur with sulfonamides; prolonged IV infusions or high doses may cause bone marrow depression (if signs occur, administer 5-15 mg/d leucovorin); caution in folate deficiency (eg, persons with chronic alcoholism, elderly persons, those receiving anticonvulsant therapy, those with malabsorption syndrome); hemolysis may occur in individuals with G-6-PD deficiency; patients with AIDS may not tolerate or respond to TMP-SMZ; caution in renal or hepatic impairment (perform urinalyses and renal function tests during therapy); give fluids to prevent crystalluria and stone formation |
| Drug Name | Cephalexin (Keflex) |
| Description | First-generation cephalosporin that inhibits bacterial replication by inhibiting bacterial cell wall synthesis. Bactericidal and effective against rapidly growing organisms forming cell walls. Resistance occurs by alteration of penicillin-binding proteins. Effective for treatment of infections caused by streptococcal or staphylococci, including penicillinase-producing staphylococci. Used orally when outpatient management is indicated. |
| Adult Dose | 250-1000 mg PO q6h for 10-14 d; not to exceed 4 g/d |
| Pediatric Dose | 25-50 mg/kg PO divided q6h; not to exceed 3 g/d |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid increases serum concentrations; coadministration with aminoglycosides increases nephrotoxic potential |
| Pregnancy | B - Usually safe but benefits must outweigh the risks.
|
| Precautions | Documented hypersensitivity with penicillin; colitis; dosage modification required with renal impairment |
| Drug Name | Cefixime (Suprax) |
| Description | Third-generation oral cephalosporin with broad activity against gram-negative bacteria. By binding to one or more of the penicillin-binding proteins, arrests bacterial cell wall synthesis and inhibits bacterial growth. Has shown poor activity against staphylococcal and enterococcal species. Cefixime compared favorably to a quinolone in one study. |
| Adult Dose | 400 mg PO qd |
| Pediatric Dose | 8 mg/kg PO qd; not to exceed 400 mg/d |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid increased serum concentration; coadministration of aminoglycosides increase nephrotoxicity; possible increase in serum carbamazepine concentration |
| Pregnancy | B - Usually safe but benefits must outweigh the risks.
|
| Precautions | Documented hypersensitivity to penicillin; impaired renal function; colitis; dosage modification needed with impaired renal function |
Further Inpatient Care
- Hospitalization is necessary for the following individuals:
- Patients who are toxemic or septic
- Patients with signs of urinary obstruction or significant underlying disease
- Patients unable to tolerate adequate PO fluids or medications
- Infants younger than 3 months with febrile UTI (presumed pyelonephritis)
- All infants younger than 1 month with suspected UTI even if not febrile
Complications
- Dehydration is the most common complication of UTI in the pediatric population. IV fluid replacement is necessary in more severe cases. Treat febrile UTI as pyelonephritis, and consider parenteral antibiotics and admission for these patients.
- Untreated UTI may progress to renal involvement with systemic infection (eg, urosepsis).
- Long-term complications include renal parenchyma scarring, hypertension, decreased renal function, and, in severe cases, renal failure.
Prognosis
- Most cases of UTI are simple, uncomplicated, and respond readily to outpatient antibiotic treatments without further sequelae.
- Appropriate treatment, imaging, and follow-up prevent long-term sequelae in patients with more severe cases or chronic infections.
- Nonsevere VUR usually resolves without permanent damage.
Patient Education
Medical/Legal Pitfalls
- UTI and pyelonephritis must be considered in younger pediatric patients with fever and/or nonspecific symptoms in order to recognize this fairly common diagnosis.
- Obtain urinalyses and urine culture in all febrile males younger than 6 months and in all febrile females younger than 24 months unless a readily apparent source of infection is present on examination.
Special Concerns
- Pregnancy must be considered in adolescent girls who present with symptoms of UTI and/or vaginitis and who are sexually active.
- Batisky D. Pediatric urinary tract infections. Pediatr Ann. May 1996;25(5):266, 269-76. [Medline].
- Belman AB. A perspective on vesicoureteral reflux. Urol Clin North Am. Feb 1995;22(1):139-50. [Medline].
- Jakobsson B, Soderlundh S, Berg U. Diagnostic significance of 99mTc-dimercaptosuccinic acid (DMSA) scintigraphy in urinary tract infection. Arch Dis Child. Nov 1992;67(11):1338-42. [Medline].
- Merrick MV, Notghi A, Chalmers N, et al. Long-term follow up to determine the prognostic value of imaging after urinary tract infections. Part 1: Reflux. Arch Dis Child. May 1995;72(5):388-92. [Medline].
- Merrick MV, Notghi A, Chalmers N, et al. Long-term follow up to determine the prognostic value of imaging after urinary tract infections. Part 2: Scarring. Arch Dis Child. May 1995;72(5):393-6. [Medline].
- Mucci B, Maguire B. Does routine ultrasound have a role in the investigation of children with urinary tract infection?. Clin Radiol. May 1994;49(5):324-5. [Medline].
- Nelson JD. 1996-1997 Pocket Book of Pediatric Antimicrobial Therapy. 12th ed. Williams and Wilkins;1996.
- Panaretto K, Craig J, Knight J, et al. Risk factors for recurrent urinary tract infection in preschool children. J Paediatr Child Health. Oct 1999;35(5):454-9. [Medline].
- Rosenfeld DL, Fleischer M, Yudd A. Current recommendations for children with urinary tract infections. Clin Pediatr (Phila). May 1995;34(5):261-4. [Medline].
- Rushton HG. Urinary tract infections in children. Epidemiology, evaluation, and management. Pediatr Clin North Am. Oct 1997;44(5):1133-69. [Medline].
- Stephens MB, Wilder L, Hsu JT. Clinical inquiries. Is screening urinalysis in children worthwhile?. J Fam Pract. Nov 2003;52(11):894-5. [Medline].
- Todd JK. Management of urinary tract infections: children are different. Pediatr Rev. May 1995;16(5):190-6. [Medline].
- Williams G, Lee A, Craig J. Antibiotics for the prevention of urinary tract infection in children: A systematic review of randomized controlled trials. J Pediatr. Jun 2001;138(6):868-74. [Medline].
- Zelikovic I, Adelman RD, Nancarrow PA. Urinary tract infections in children. An update. West J Med. Nov 1992;157(5):554-61. [Medline].
Pediatrics, Urinary Tract Infections and Pyelonephritis excerpt Article Last Updated: Feb 27, 2006
|